Surf Air leads airlines higher
SRFM is up 22.6%, and a Nasdaq sector-leaders piece from BNK Invest puts it at the top of an airline group that was up about 2.6% on the day, with Surf Air Mobility cited at roughly +13.3% at midday and American Airlines +4.3%. The same piece flags semiconductors as the other relative leader, up about 2.3% as a group, led by MaxLinear (+11.9%) and Tower Semiconductor (+7.4%). No company-specific reason for Surf Air is given, it's framed purely as a sector move.
VerifyMe reverse split and merger vote
VRME is down 18.0%, and there's real news behind it. The company will do a 1-for-10 reverse stock split effective 12:01 a.m. ET on September 29, trading post-split on Nasdaq under the same ticker from Monday's open. Stockholders had approved a range of 1-for-2 to 1-for-10 back at the October 2025 annual meeting, and the board picked the maximum ratio. Fractional shares round up, authorized share count is unchanged. Separately, at Thursday's annual meeting shareholders approved the OpenWorld merger, specifically the issuance of more than 20% of VerifyMe common stock to OpenWorld holders and the potential change of control under Nasdaq rules, by 6,071,943 for to 89,082 against. All five directors were elected, say-on-pay and the 2020 equity plan amendment passed, and MaloneBailey was ratified as auditor. Two charter proposals failed: a new class of blockchain common stock, and the related distribution changes plus a name change to OpenWorld, Inc. The $0.15 special cash dividend declared September 18 is conditional on the merger closing and becomes $1.50 per share post-split if it does. The merger deadline was extended to October 31, 2026, the third amendment to the agreement. Two 8-K filings covering the rights modification, charter amendment and the shareholder vote are in the list, and there's a meeting transcript that's paywalled past the opening remarks.
Credo options and ETF flows
CRDO is up 7.7%. Two items, neither of which explains the move. Options volume hit 65,665 contracts, about 6.6 million underlying shares or roughly 70% of the 9.4 million average daily volume, with the September 25 $195 call the busiest line at 6,596 contracts. Separately, ETFs were net sellers of $36.0 million on September 23, with 12 funds buying and 11 selling. SOXX did most of the selling, cutting its stake 3.46% for $28.0 million, and BAI trimmed 3.49% for $8.8 million. That followed $14.3 million of net buying on the 22nd and a $22.1 million net sale on the 21st.
Generac on the Amazon contract
GNRC is up 5.2%. UBS reiterated Buy with a $340 target following the September 16 long-term supply agreement to provide backup generators for Amazon data centers. The near-term portion is worth $2.4 billion, with the full contract up to $8 billion. Generac's data center backlog was $1.6 billion as of Q2 2026, against $150 million in contracted orders a year earlier. UBS cut its 2027-28 residential sales growth assumption to 5% and legacy commercial/industrial to 6%, both from 7.5%, citing higher interest rates, and raised its 2028 adjusted EBITDA estimate by $24 million net (minus $27 million from the weaker residential and C&I outlook, plus $51 million from data centers). The article notes the stock at $198.05, up 45% year to date, against a 52-week high of $296.44, and lists earlier notes from Needham (Buy, $283), Barclays (Equalweight, $278) and Cantor Fitzgerald ($333). Amazon also received a seven-year warrant for up to 1,693,745 shares at $200.93.
Costco Q4 plus a round of target cuts
COST is up 2.9% after fiscal Q4 results. Net sales rose 11.2% to $93.9 billion in the 16-week quarter, diluted EPS was $6.75 against $5.87 a year ago, including a one-time $0.15 benefit from IEEPA tariff refunds net of reinvestment in member value. Total comps were up 9.4%, but 6.7% excluding fuel and FX; US comps 10.7%, or 7.2% adjusted, with Canada at 4.6% adjusted. Digitally enabled sales grew 19.5% and membership fee income rose to $1.85 billion from $1.72 billion. Full year: sales up 10.1% to $297.2 billion, EPS $20.76 versus $18.21, year-end cash of $20.2 billion and 939 warehouses. Worth noting that three analysts all trimmed targets into these numbers, per headlines only: Wells Fargo to $950, Mizuho to $1,065, Bernstein to $1,143 with Outperform kept. Other headlines flag a $7.5 billion capex plan for fiscal 2027 and the earnings call transcript.
Vertiv acquisition and coverage note
VRT is up 3.2%. A subsidiary signed a definitive agreement to acquire King Environmental Services Ltd., expected to close in Q4 2026, with terms undisclosed and no guidance on financial impact. A GuruFocus piece also recaps a Wells Fargo Overweight initiation at a $340 target, though it dates that initiation to October 2023, so treat it as background rather than today's news; the same piece has GuruFocus calling the stock 43.6% overvalued against a $175.83 GF Value at $252.48, a GF Score of 87, and $3.88 million of insider selling over three months. Vertiv also shows up as a holding in iShares S&P 500 Growth (IVW), which saw roughly $142.4 million of outflows week over week.
Canaan move has no matching news
CAN is down 4.6% and nothing in the list explains it. The three full-text items tagged to that ticker are keyword false matches: a Trump post congratulating Jerry Kassar on re-election as New York Conservative Party chairman, a wire headline saying Russia could immediately restart 80% of its Black Sea and Azov grain port capacity if diplomacy succeeds with three terminals at 20% of capacity badly damaged and needing months of repair, and a USTR Greer line that the US has reached agreements with China on a subset of tradeable goods. None of them concern the company.
Oracle, the heaviest headline cluster
ORCL is down 1.8% on by far the largest volume of headlines here, all headline-only. The recurring thread is the Project Jupiter data center delay and force-majeure notices, which several outlets tie to a wider debate about AI financing and credit spreads, with SoftBank shares reportedly falling on the same warning. Stifel is reported reiterating Buy through it. Alongside that sit a Goldman note on hyperscaler AI debt and a figure of AI capex rising 54% to $1.2 trillion in 2027 across the five largest US hyperscalers, plus Michael Burry warning on possible AI write-offs at Microsoft, Amazon and Oracle. A Surescripts partnership on prior authorization and a Form 4 round out the list. I haven't read any of these in full.
Nebius, Apple and the rest
NBIS is down 2.6% despite a cluster of headlines describing a BNP Paribas upgrade to Outperform with the target raised to $399 and intraday gains of 5-8%, so today's quote runs against the tone of those items. AAPL is up 1.5% with a long run of ETF holdings-change headlines and a Bernstein note, headline-only, saying December-quarter earnings could disappoint on higher memory costs, with EPS cut to $2.87 from $3.00 versus $2.92 consensus while keeping Outperform. Qualcomm's Apple licensing renewal appears in the same cluster. CELU is up 5.7% but the only item is a Nasdaq earnings page for FQE Jun/2026 with a single estimate and no actual data populated, so there's nothing there.
Everything else quiet
The remaining names are routine: CRSP -2.6% and RVMD +2.6% on Form 4 and Form 144 filings, including a $1.96 million director sale at Revolution Medicines, NTAP +2.0% on a Form 144 and a chart note, IOVA +1.8% at a 52-week high of $10.98, and small moves in ALAB, APH, NFLX, AMC, AVGO, MPC, TSM, SPCX, RKLB, INCY, AFL, BFLY and FPS, mostly ETF holdings updates, insider filings and analyst target tweaks with no move behind them.
Celularity raises $10m, biggest move on the list
CELU is up 14.8%, and there is real news behind it. Celularity closed an initial tranche of a private placement of senior secured convertible notes and warrants generating over $10 million gross, the first step in a recapitalisation that contemplates up to $25 million of new cash plus restructuring of roughly $3 million of existing debt. The notes run 24 months at 10% annual interest compounded annually, convertible into Class A stock at $1.50, with five-year warrants struck at the same price. Management says it has cut monthly cash burn by more than $1 million through personnel and resource changes, and expects positive monthly operating cash flow by the end of Q1 2027, based on higher manufacturing revenue and deployment of existing inventory. That inventory is cenplacel-L, its placenta-derived cell therapy, which management estimates at about $40 million of potential sales value in jurisdictions where supply is legally authorised. Philip A. Barach joins a newly constituted five-member board alongside Robert Hariri and Peter Diamandis, with two more directors to come. Odeon Capital was placement agent. The second CELU item, a Nasdaq earnings calendar page, contains no actual data.
Planet Labs up 7.6% with no stated cause
PL rose 7.6% to $17.62. The GuruFocus piece covering it gives no reason for the move, only valuation commentary: GF Value of $5.61 against the $17.62 price, a GF Score of 63 with momentum 8/10 and growth 7/10 but valuation 1/10 and profitability 2/10, a 52-week range of $10.52 to $51.76, and insider selling of $52.6 million over the past twelve months. Seven gurus hold it, four adding and three trimming. Note that the second item tagged PL is actually about Planet Ventures Inc (PNXPD), an unrelated Canadian investment issuer whose CEO Etienne Moshevich resigned effective immediately. That one has nothing to do with your position.
Nebius jumps on BNP upgrade and October price rises
NBIS is up 7.4%, and this is the busiest name in the list with seven full-text reads. The driver is BNP Paribas Exane, where Stefan Slowinski moved the rating from Neutral to Outperform and lifted the target to $399 from $260. The stock closed $243.44 against a prior close of $226.61. The reasoning runs through pricing: Nebius told customers that from October 1 it is raising on-demand GPU cloud prices on Nvidia H100, H200, B200 and B300 instances by roughly 17–21%, and AMD EPYC Genoa CPU rates by around 25%, the second increase in a matter of months. Investing.com frames that as a signal of tight compute capacity rather than cost pass-through, with Q2 AI cloud revenue of $574.9 million and an adjusted EBITDA margin near 50% underneath it. BNP's number is roughly $22 billion of annual recurring revenue by end-2027. Fintel adds the surrounding analyst picture: consensus target mean $289.19 and median $306.00 as of September 15, 25 ratings split 72% positive, with Rothschild initiating at Sell on September 21 and Truist at Buy on September 9. Q2 came in at EPS of -0.12 against -0.6358 estimated and revenue of $582.3 million against $584.2 million expected; next earnings October 22. The August filings noted most deals were signed against capacity arriving late 2026 feeding 2027 revenue, a first capacity auction pilot at the highest Blackwell price to date, and a $5.75 billion convertible note offering closed August 24. One caution on the GuruFocus coverage: it repeats a GF Score of 55, a price-to-sales ratio around 50 against a historical median of 6.94, and insider selling of $179.9 million over twelve months with no purchases, against eight gurus of whom seven added. One of those GuruFocus pieces is internally inconsistent, dating the upgrade to October 2023 and naming a different analyst.
CoreWeave upgrade on the same pricing theme
Filed under NBIS but about CoreWeave: JPMorgan's Samik Chatterjee moved CRWV to Overweight and raised his December 2027 target to $125 from $120. Same logic as the Nebius call. He points to 25% price changes across CoreWeave products in July, frequent increases at Nebius, short-term compute at some rivals running near three times CoreWeave's long-term contract rate, Q3 contracts at about $40 million per megawatt, and management's claim that higher pricing adds 5 to 10 points to contribution margin on new contracts. Contracted power was 4.2 gigawatts as of August 11, up from 3.1 at the end of 2025. Worth reading the two calls together: the neocloud pricing cycle is what both banks are underwriting.
Iovance reinstated at Buy by Goldman
IOVA is up 6.0%. Goldman Sachs reinstated coverage with a Buy and a $15 target, the stated rationale being that early logistical and operational hurdles around the Amtagvi (lifileucel) launch are easing, which should lift gross margins. Market cap around $4.6 billion. The GuruFocus framing is mixed: GF Score of 32, profitability 1/10 against financial strength 7/10, current ratio 4.35 and Altman Z-Score 10.76, trailing EPS of -0.72, and price-to-sales of 12.9 versus a historical median near 11. Momentum has been extreme, with the stock up 180.7% over 24 weeks and 392.3% over 52. One guru holds and has added; no insider trading reported. A second GuruFocus write-up of the same call gives slightly different figures and a wrong date, so treat the exact numbers loosely.
Revolution Medicines, insider selling into strength
RVMD is up 4.8%. The two full-text items are Form 144 and Form 4 filing notices with no substance in the body. The headlines around them say director Elizabeth Anderson sold $1.96 million of stock, and that Goldman Sachs reinstated coverage with a Buy and a $267 target. Those are headline-only, so no reasoning behind the Goldman call here.
Rocket Lab and Xenon
RKLB is up 4.7% on headline-only items: a GuruFocus note citing a GF Score of 74 and calling the stock overvalued on GF Value, a report that Cathie Wood added again, and two TradingView chart posts pointing in opposite directions. XENE is up 4.1%, with only a conference appearance at TD Cowen's neuropsychiatry event and a TradingView headline claiming a 30% crash, which does not square with the quoted move. Nothing here to act on without a closer look.
Oracle down 3.5% on Project Jupiter force majeure
ORCL is the biggest decliner and by far the largest headline cluster, though all of it is headline-only. The core event: Oracle sent a force majeure notice to the developer of its New Mexico data centre, Project Jupiter, a 2.45GW site tied to the Stargate buildout, reportedly to limit its exposure to payments if regulatory and infrastructure setbacks delay delivery toward the 2028 target. Oracle's own line, per the wire headlines, is that force majeure notices are commonplace at this scale and are used to preserve contractual rights. Shares were down around 5% premarket on the report. Stifel reiterated Buy through it. Around that sits a broader AI-financing argument: Goldman expects the five largest US hyperscalers to lift AI infrastructure spending 54% to $1.2 trillion in 2027, Michael Burry warns Microsoft, Amazon and Oracle could face AI write-offs, and separate headlines note Oracle's AI debt is trading at a wider spread and that the Blue Owl project delay is rippling through AI financing, with SoftBank falling in sympathy. Separately and more mundanely: Oracle Japan reported cloud revenue up 32% with margin expansion, Oracle Health partnered with Surescripts on prior authorisation and with ID.me on digital identity, and there were insider sales from CEO Michael Sicilia ($3.42m) and EVP Maria Smith ($399k). If you look at one name today, this is it.
Costco earnings
COST is down 0.9% after Q4 FY26. From the headlines and the posted summary: net sales up 11.2% year on year to $93.9 billion, net income up 14.9% to $3.00 billion, comparable sales up 9.4% with US up 10.7%, comps ex-fuel and FX up 6.7%, digitally enabled sales up 19.5%, and EPS of $6.75 against an estimate of $6.48. A separate headline flags a $7.5 billion expansion plan. All headline-level, no full text read.
Everything else, briefly
The rest of the list is small moves and routine filings. SNDK is down 3.5% amid AI memory headlines alongside Micron. FPS is down 2.3% after Wells Fargo initiated at Equal Weight. BFLY is up 2.3% with CEO Joseph DeVivo selling 5,980 shares for about $60k. VRME is up 1.7% after shareholders approved the OpenWorld merger. Vertiv, down 1.4%, agreed to acquire King Environmental Services for EMEA expansion. AMC is up 1.4% having priced $2 billion of notes and an $850 million loan, and shareholders approved the equity plan amendment while rejecting board changes. SOUN launched OASYS Edge for embedded voice agents. Broadcom, Apple, TSMC, NetApp, Generac, Mercury Systems and Netflix are all inside 1.5% with insider filings, chart posts and analyst reiterations and nothing that needs your attention today. PGY and NVTS show zero change but carry GuruFocus headlines referencing earlier declines of 9.9% and 5.0% respectively, so those are stale.
Celularity up 14.8% on recapitalisation
CELU is the biggest mover on the list, up 14.8%, and there's a real event behind it. Celularity completed an initial closing of a private placement of senior secured convertible notes and warrants, raising over $10 million gross. That's the first tranche of a broader recapitalisation contemplating up to $25 million of new cash and the restructuring of roughly $3 million of existing debt. The notes run 24 months at 10% annual interest compounded annually, initially convertible at $1.50, with five-year warrants also struck at $1.50. Management says it has cut monthly cash burn by more than $1 million through personnel and resource changes, and expects positive monthly operating cash flow by the end of Q1 2027, based on higher manufacturing revenue and deployment of existing inventory. It holds inventory of cenplacel-L, its placenta-derived cell therapy, which management puts at roughly $40 million in potential sales value, to be sold through commercial relationships in jurisdictions where that's legally permitted. Philip Barach joins a newly constituted five-member board alongside Robert Hariri and Peter Diamandis, with two more directors to be named. Odeon Capital Group was placement agent. The separate Nasdaq earnings-calendar item for CELU carries no actual data.
Nebius up 7.4% on BNP Paribas upgrade
NBIS rose 7.4% and the driver is unambiguous: BNP Paribas Exane moved it from Neutral to Outperform and lifted its target to $399 from $260, against a prior close of $226.61. Investing.com ties the call to the pricing news behind it. Nebius told customers that from October 1 it is raising on-demand GPU cloud prices on Nvidia H100, H200, B200 and B300 instances by roughly 17–21%, and AMD EPYC Genoa CPU rates by about 25%, the second increase in a matter of months, which investors are reading as evidence of tight compute capacity rather than cost pass-through. Q2 AI cloud revenue was $574.9 million with adjusted EBITDA margin near 50%. GuruFocus reports BNP's analyst as seeing close to $22 billion in annual recurring revenue by end-2027. The move happened against a flat-to-weak tape, so it was company-specific. Some cross-checks worth having: the Fintel/Nasdaq write-up notes Rothschild initiated at Sell on September 21 and Truist at Buy on September 9, consensus target mean $289.19 as of September 15, Q2 EPS of -0.12 against -0.6358 expected on revenue of $582.3 million, a $5.75 billion convertible note offering closed August 24, and next earnings October 22. GuruFocus flags a price-to-sales ratio around 50 against a historical median of 6.94, a GF Score of 55 with momentum 9/10 and valuation 2/10, and $179.9 million of insider selling over twelve months with no purchases, while seven of eight tracked gurus added. Note the GuruFocus pieces contradict each other on the P/S figure and one carries a stale 2023 date and a different analyst name, so treat their detail loosely. Two TradingView posts cover the same name technically, one watching a symmetrical triangle with resistance around $240–$250, the other a $244.69 line. Related: JPMorgan upgraded peer CoreWeave to Overweight with a $125 target, citing short-term compute contracts at premium rates adding 5 to 10 points to contribution margins, and explicitly pointing at frequent price increases at Nebius as evidence of the pricing trend.
Planet Labs up 7.6%, with a name-confusion caveat
PL rose 7.6% to $17.62. The GuruFocus piece on it offers no news reason, just valuation commentary: GF Value of $5.61 against the price, a GF Score of 63 with growth 7/10 and momentum 8/10 but valuation 1/10 and profitability 2/10, a 52-week range of $10.52 to $51.76, and $52.6 million of insider selling over the past twelve months. No catalyst is stated for the move. Be aware a second item filed under PL is actually about Planet Ventures Inc (PNXPD), an unrelated Vancouver investment issuer with a $13 million market cap, whose CEO Etienne Moshevich resigned effective immediately. That one has nothing to do with Planet Labs.
Iovance up 6.0% on Goldman reinstatement
IOVA gained 6.0% after Goldman Sachs reinstated coverage with a Buy and a $15 target. Goldman's stated reasoning is that Iovance is getting past the early logistical and operational hurdles of the Amtagvi (lifileucel) launch, its TIL therapy for unresectable or metastatic melanoma, which should lift gross margins. GuruFocus puts the market cap near $4.6 billion, GF Score 32, price-to-sales 12.9 versus a historical median around 11, TTM EPS of -0.72, strong liquidity (current ratio 4.35, Altman Z-Score 10.76), and notes the stock is up 392% over 52 weeks. One guru holds and has added; no insider activity either way.
Revolution Medicines and Rocket Lab
RVMD was up 4.8%. The two full-text items here are bare SEC filing stubs, a Form 4 and a Form 144, with no content beyond the headline. Separate headline-only items say director Elizabeth Anderson sold $1.96 million of stock, and that Goldman Sachs reinstated coverage with a $267 target. RKLB was up 4.7%, with headline-only items noting Cathie Wood added again and a GuruFocus GF Score of 74 calling it overvalued, plus two conflicting TradingView chart posts. XENE was up 4.1% with only headline items, including a TradingView post headlined as a 30% crash, which doesn't square with the quoted move, and a conference appearance.
Oracle down 3.5% on Project Jupiter force majeure
The largest cluster on the list by item count is ORCL, down 3.5%, and all of it is headline-only. The recurring thread: Oracle sent a force majeure notice to the developer of Project Jupiter, its roughly 2.45GW New Mexico data centre tied to the Stargate buildout, with headlines pointing to power supply and regulatory setbacks, public opposition, and risk to a 2028 target. Oracle's own line, per a headline, is that force majeure notices are commonplace at this scale and preserve contractual rights. Knock-on headlines: SoftBank shares fell on the same news, and a report says the Oracle/Blue Owl project delay is rippling through AI financing. Stifel reiterated Buy. Separately there are headlines on Goldman seeing hyperscaler AI capex rising 54% to $1.2 trillion in 2027, Michael Burry warning on AI write-offs at Microsoft, Amazon and Oracle, Oracle Japan posting 32% cloud revenue growth, Oracle Health partnerships with Surescripts and ID.me, and insider sales by CEO Michael Sicilia ($3.42m) and EVP Maria Smith ($399k). I haven't read any of these in full.
Costco earnings and the rest
COST was down 0.9% despite Q4 FY26 numbers that headlines describe as net sales up 11.2% to $93.9 billion, net income up 14.9% to $3.00 billion, comps up 9.4% with US up 10.7%, and EPS of $6.75 against a $6.48 estimate, plus a headline flagging a $7.5 billion expansion plan. Headline-only. SNDK fell 3.5% with no explanation in the items, just IBD coverage of memory names attempting buy points. Elsewhere it's quiet: Vertiv is buying King Environmental Services for EMEA expansion, AMC priced $2 billion of notes and an $850 million loan and shareholders approved an equity plan amendment while rejecting board changes, VerifyMe holders approved the OpenWorld merger, SoundHound launched OASYS Edge, and Bernstein initiated Amphenol at Outperform. Broadcom, Apple, TSMC, NetApp, SpaceX and the rest are sub-1.5% moves with routine filings, insider sales and chart posts behind them.
Celularity recapitalizes, stock up 14.4%
Celularity is the biggest mover on the list, up 14.4% after closing an initial tranche of a recapitalization. It raised over $10 million gross from a private placement of senior secured convertible notes and warrants, part of a plan contemplating up to $25 million in new cash and restructuring roughly $3 million of existing debt. The notes run 24 months at 10% annual interest compounded annually, convertible at $1.50, with five-year warrants also struck at $1.50. Management says monthly cash burn is down by more than $1 million through personnel cuts and resource reallocation, and it expects positive monthly operating cash flow by the end of Q1 2027, based on higher manufacturing revenue and deploying existing inventory. That inventory is cenplacel-L, its investigational placenta-derived cell therapy, which management estimates at about $40 million in potential sales value, to be sold through commercial relationships in jurisdictions where that is legally permitted. Philip Barach joins a newly constituted five-member board alongside Robert Hariri and Peter Diamandis, with two seats still to be named. Odeon Capital was placement agent, and further closings are not guaranteed.
Nebius upgrade and the pricing story
Nebius is up 7.5%, and there are seven items on it covering the same event from different angles. BNP Paribas Exane's Stefan Slowinski moved the stock from Neutral to Outperform and raised his target to $399 from $260, about 76% above the prior close of $226.61. The substance behind the call is pricing: Nebius told customers that from October 1 it is raising on-demand GPU cloud prices on Nvidia H100, H200, B200 and B300 instances by roughly 17-21%, and AMD EPYC Genoa CPU rates by about 25%, the second increase in a matter of months. Q2 AI cloud revenue was $574.9 million with an adjusted EBITDA margin near 50%, and BNP's case runs to nearly $22 billion in annual recurring revenue by end-2027. The move was company-specific, with the Nasdaq, S&P and Dow all slightly lower on the day. A related JPMorgan note makes the same argument at CoreWeave, upgraded to Overweight with a $125 December 2027 target, citing 25% price changes in July, roughly $40 million per megawatt on Q3 contracts, contracted power up to 4.2 gigawatts from 3.1 at end-2025, and management's claim that higher pricing adds 5 to 10 points to contribution margins on new deals. The counterweight: Michael Burry said in a September 22 Substack post that he added "in some size" to shorts in Nebius, Micron, Palantir and the SOXX semiconductor ETF, pointing to Acer CEO Jason Chen's comment that DDR4 has "more sellers than buyers" and calling the Nasdaq 100 historically overvalued and top-heavy. GuruFocus notes Nebius trades around 50x sales against a historical median near 7, insiders have sold $179.9 million over twelve months with no buying, while 7 of 8 tracked gurus added.
Planet launches Amazon.ia
Planet Labs is up 7.9% after announcing Amazon.ia, a multi-partner initiative to monitor Amazon biodiversity using satellite imagery and AI. The Bezos Earth Fund granted more than $14 million across the Andes Amazon Fund and the World Resources Institute. Planet is a founding partner among more than two dozen organizations including MIT, Arizona State, Cornell Lab of Ornithology, Microsoft AI for Good Lab, Smithsonian ForestGEO, WCS and WWF. The programme combines satellite and ground data to produce change alerts, biodiversity status and protected-area effectiveness assessments. The article does not disclose any revenue to Planet from the initiative.
Iovance reinstated at Buy
Iovance is up 6.0% after Goldman Sachs reinstated coverage with a Buy and a $15 target. Goldman's stated reasoning is that early logistical and operational hurdles around the launch of Amtagvi, its approved tumor-infiltrating lymphocyte therapy for unresectable or metastatic melanoma, are easing, which should improve gross margins. The accompanying data: market cap around $4.6 billion, price-to-sales of 12.9 against a historical median near 11, trailing EPS of -0.72 with deeply negative operating margins, but strong liquidity with a current ratio of 4.35 and an Altman Z-Score of 10.76. The stock is up 180% over 24 weeks and 392% over 52 weeks. One tracked guru holds and has added; no insider trades reported.
Surf Air's second software contract
Surf Air Mobility is up 5.0% on two announcements. It signed a definitive agreement with SkyDance Air for OperatorOS, its second commercial contract for the product, earning a percentage of revenue on all SkyDance flights run through the software. SkyDance operates three aircraft, is the second largest single-fleet operator of Cirrus Vision Jets in North America, and plans to expand to roughly 10 aircraft in 2027. Surf Air's stated goal is five operators live on the platform by end-2026. OperatorOS is powered by Palantir, has run Southern Airways and Mokulele internally since 2025, and was recently approved by the FAA as an authorized system of record for electronic signatures and recordkeeping. Separately, Barrett Brown was named President of SurfOS effective September 30; he spent 2013 to 2024 at Palantir, including as Head of Asia from 2018, and later was VP and Head of APAC at Maxar.
Oracle force majeure cluster
Oracle is down 3.3% and carries by far the most headlines here, all circling one event. Reports say Oracle sent a force majeure notice to the developer of Project Jupiter, a large New Mexico data center tied to the Stargate buildout, with headlines citing regulatory, power supply and public opposition issues and risk to a 2028 AI data center target. A quoted Oracle line says force-majeure notices are commonplace in developments of this scale and are often used to preserve contractual rights among project partners. Separate headlines flag Oracle AI-linked debt trading at a wider spread, several Form 4 insider sales including CEO Michael Sicilia at $3.42 million and EVP Maria Smith at $399,122, an Oracle Japan Q1 FY27 report with cloud revenue up 32%, and partnerships with Surescripts on prior authorization and ID.me on digital identity. These are headline-only, so the detail behind the force majeure story isn't in hand.
Rocket Lab and the ARK buy
Rocket Lab is up 4.8%, with six headlines all pointing at the same thing: Cathie Wood's ARK bought about $25 million of the stock while selling Alphabet, ahead of an upcoming mission. Headline-only, so no further detail. Two technical-analysis headlines on the name point in opposite directions.
Other analyst notes and smaller movers
Revolution Medicines is up 4.6% on a Goldman Sachs reinstatement at Buy with a $267 target, headline-only. Xenon is up 4.0% with one headline flagging a 30% crash and a conference appearance, which don't obviously fit together from headlines alone. Teva is up 3.0%, with Oppenheimer initiating at Outperform and a Bank of America healthcare conference transcript. TPX.L is up 4.1%, described as 8.5% on 1.5 times its own ATR20 but on only 0.1 times average volume. On the downside, SanDisk is off 3.4% with a mix of bullish chart headlines and a note about a $2,400 target, and Broadcom is down 1.3%, with headlines citing an FT report that China is reviewing Broadcom switch use in state-backed data centers and a note on its $230 billion AI target.
The rest
Everything else on the list moved about a percent or less. Apple has a long headline tail, mostly the extended Qualcomm patent licensing agreement, a BofA note keeping a $370 target while flagging mixed iPhone 18 demand signals, and assorted chart pieces, but the stock is down just 0.3%. Amphenol drew a Bernstein initiation at Outperform, TeraWulf a UBS initiation at Buy, and On Holding target raises from BMO to $33, Barclays to $44 and Needham to $40. None of those names moved more than 1.2%. Nothing there needs a second look today.
Celularity recapitalises, up 14.4%
Celularity is the biggest mover on the list, up 14.4% after closing the first tranche of a recapitalisation that brought in over $10 million gross from a private placement of senior secured convertible notes and warrants. The full plan contemplates up to $25 million of new cash plus restructuring of roughly $3 million of existing debt. The notes run 24 months at 10% annual interest compounded annually, initially convertible at $1.50 a share, with five-year warrants also struck at $1.50. Management says it has cut monthly cash burn by more than $1 million through headcount and resource changes and expects positive monthly operating cash flow by the end of Q1 2027, based on higher manufacturing revenue and selling down existing inventory. It holds inventory of cenplacel-L, its placenta-derived cell therapy, which management puts at roughly $40 million of potential sales value, to be deployed through commercial relationships where legally permitted. Philip Barach joins a newly constituted five-member board alongside Robert Hariri and Peter Diamandis, with two more directors to come. Odeon Capital was placement agent, and further closings are not guaranteed.
Planet up 7.9% on Amazon.ia launch
Planet Labs is up 7.9%. It announced Amazon.ia, a multi-partner effort to monitor biodiversity across the Amazon using satellite imagery and AI, with the Bezos Earth Fund granting more than $14 million across the Andes Amazon Fund and the World Resources Institute. Planet is a founding partner among more than two dozen organisations, including MIT, Arizona State, Microsoft's AI for Good Lab, the Smithsonian, WCS and WWF. The programme is meant to deliver change alerts, biodiversity status, ecosystem condition and protected-area effectiveness data. Note the article describes a grant-funded initiative and does not disclose revenue to Planet.
Nebius upgrade and the neocloud pricing story
Nebius is up 7.5%, and the whole cluster of items traces back to one call: BNP Paribas Exane's Stefan Slowinski moved the stock from Neutral to Outperform and lifted his target to $399 from $260, which was about 76% above the prior close of $226.61. The reasoning is pricing power. Nebius told customers that from 1 October, on-demand Nvidia H100, H200, B200 and B300 instances go up roughly 17 to 21%, and AMD EPYC Genoa CPU rates about 25%, the second increase in a matter of months, read as tight compute capacity rather than cost pass-through. Behind it sits Q2 AI cloud revenue of $574.9 million at an adjusted EBITDA margin near 50%, and BNP's view that annual recurring revenue could approach $22 billion by end-2027. The move came against a flat-to-down tape, so it was company-specific. The same theme shows up in JPMorgan's upgrade of CoreWeave to Overweight with a $125 December 2027 target, where Samik Chatterjee cited 25% price changes across CoreWeave products in July, frequent increases at Nebius, third-quarter contracts at about $40 million per megawatt, 5 to 10 points of added contribution margin on new contracts, and contracted power up to 4.2 gigawatts as of 11 August from 3.1 gigawatts at end-2025. Cutting the other way, Michael Burry said in a 22 September Substack post that he added "in some size" to shorts in Nebius, Micron, Palantir and the SOXX semiconductor ETF, calling the Nasdaq 100 historically overvalued and top-heavy, and citing Acer CEO Jason Chen's comment that DDR4 has "more sellers than buyers" even as LPDDR5 and DDR5 9600 stay tight. GuruFocus adds context: Nebius trades on a price-to-sales ratio around 50 against a historical median of 6.94, is unprofitable and cash-flow negative, GF Score 55 out of 100, with $179.9 million of insider selling over twelve months and no insider buying, against seven of eight tracked gurus adding. A separate Nasdaq piece notes NBIS as a holding in IXUS, which saw roughly $146.8 million of outflows week over week.
Iovance up 6.0% on Goldman reinstatement
Iovance is up 6.0% after Goldman Sachs reinstated coverage with a Buy and a $15 target, pointing to easing early operational and logistical hurdles on the Amtagvi (lifileucel) launch as a driver of better gross margins. Amtagvi is the approved autologous TIL therapy for certain unresectable or metastatic melanoma patients. The accompanying GuruFocus data is less flattering: market cap around $4.6 billion, price-to-sales of about 12.9 versus a historical median near 11, trailing EPS of -0.72 and deeply negative operating margins, GF Score of 32 out of 100 with profitability at 1 out of 10. Balance sheet looks solid, with a current ratio of 4.35 and an Altman Z-Score of 10.76, and the stock is up 392% over 52 weeks. One guru holds and has been adding; no insider trades reported.
Surf Air up 5.0% on second OperatorOS deal
Surf Air Mobility is up 5.0% on two items. It signed a definitive agreement with SkyDance Air for its OperatorOS flight operations software, its second commercial OperatorOS contract, against a stated goal of five operators live by end-2026. Surf Air earns a percentage of revenue on all SkyDance flights run through the software. SkyDance flies three aircraft, is the second largest single-fleet operator of Cirrus Vision Jets in North America, and plans to reach about 10 aircraft in 2027. OperatorOS is powered by Palantir, has run Southern Airways and Mokulele internally since 2025, and was recently approved by the FAA as an authorised system of record for electronic signatures and recordkeeping. Separately, the company named Barrett Brown President of SurfOS effective 30 September. Brown spent 2013 to 2024 at Palantir, latterly as Head of Asia, and more recently advised Turion Space after a spell as VP and Head of APAC at Maxar.
Rocket Lab up 4.8%, ARK buying
Rocket Lab is up 4.8%, with a cluster of headline-only items saying Cathie Wood's ARK bought roughly $25 million of shares while trimming Alphabet, and that Rocket Lab is preparing for a mission. Two TradingView posts take opposite technical views. No full text read on any of these.
Revolution Medicines and other analyst headlines
Revolution Medicines is up 4.6%, with headlines saying Goldman Sachs reinstated coverage with a Buy and a $267 target. Teva, up 3.0%, has a headline noting Oppenheimer initiated at Outperform. Xenon is up 4.0% on headline-only items about a TD Cowen conference appearance and a TradingView post referring to a 30% crash. Tempur Sealy's London line is up 4.1% on a chart-flag item only. Elsewhere on analyst notes: Bernstein initiated Amphenol at Outperform, UBS initiated TeraWulf at Buy citing leasing growth, Truist raised its Axsome target to $285, and BMO, Barclays and Needham all raised On Holding targets, to $33, $44 and $40 respectively. All headline-only.
Oracle down 3.3% on Project Jupiter force majeure
Oracle is the largest decliner in the section at -3.3%, and it carries by far the heaviest news flow, all headline-only. The driver is a report that Oracle sent a force majeure notice to the developer of its New Mexico data center, Project Jupiter, tied to the Stargate buildout, with headlines describing regulatory, power supply and public opposition setbacks and risk to a 2028 AI data center target and a 2.45GW facility. One wire flash notes Oracle's position that force majeure notices are commonplace at this scale and are often used to preserve contractual rights. Premarket and intraday flashes put the fall at 5.1% to 5.4% at the time. Around that, there are separate items on AI-linked debt trading at a wider spread, said to be 37 basis points, a GuruFocus note putting GF Value at $192.32 against a $144.56 price, insider sales by CEO Michael Sicilia ($3.42m) and EVP Maria Smith ($399,122), Oracle Japan Q1 FY27 results with cloud revenue up 32% and expanding margins, and partnership items with Surescripts on prior authorisation and ID.me on digital identity, plus a digital assets platform expansion for banking.
SanDisk down 3.4%
SanDisk is down 3.4%. The items on it are all headline-only and pull in different directions: two TradingView pieces framing it as breaking resistance or an ascending triangle breakout, a GuruFocus line about a $2,400 target testing AI storage assumptions, an Investing.com outlook piece for year-end and 2027, and IBD market wraps mentioning Micron and SanDisk sinking in buy zones.
Apple, Broadcom and the quieter names
Apple is only down 0.3% despite a very long headline list, so nothing there demands attention on price. The recurring threads are a Qualcomm-Apple patent licensing extension, Bank of America reiterating a $370 target while flagging mixed iPhone 18 demand signals, UBS staying neutral on iPhone wait times, a Pete Sessions IRA sale, and coverage of the Epic Games litigation. Broadcom is down 1.3% on headlines about an FT report that China is reviewing Broadcom switch use in state-backed data centers, plus routine Form 4 and 144 filings. Everything else on the list moved by 2% or less. Worth a glance only: AMC priced $2 billion of notes and an $850 million loan, Vertiv agreed to buy King Environmental Services for EMEA expansion, SoundHound launched OASYS Edge for embedded voice agents, and Google plans to test custom AI chips in space on an upcoming SpaceX mission, with a separate filing showing SpaceX President Gwynne Shotwell registering to sell nearly $52 million of stock. Costco reports after the close today.
Surf Air Mobility up 14.8% on second software contract
The biggest move on the list is SRFM, up 14.8%, and there are two pieces of company news behind it. Surf Air signed a definitive agreement with SkyDance Air for its OperatorOS flight operations software, its second commercial OperatorOS contract, against a stated goal of five operators live on the platform by the end of 2026. Surf Air earns a percentage of revenue on all SkyDance flights run through the software. SkyDance operates three aircraft, is described as the second largest single-fleet operator of Cirrus Vision Jets in North America, and plans to grow to roughly 10 aircraft in 2027. OperatorOS handles aircraft and crew scheduling, flight management, reporting and distribution for Part 135 operators, is powered by Palantir, has been running Surf Air's own Southern Airways and Mokulele operations since 2025, and was recently approved by the FAA as an authorised system of record for electronic signatures and recordkeeping. Separately, the company named Barrett Brown president of SurfOS effective 30 September. Brown spent 2013 to 2024 at Palantir, latterly as Head of Asia, and was previously VP and Head of APAC at Maxar. He will run commercialisation and expansion across the three SurfOS products, BrokerOS, OperatorOS and OwnerOS, of which the first two now have definitive external customer agreements.
Pagaya down 9.9% with no stated cause
PGY fell 9.9% to $18.72 on volume of 6.65 million against a 3.0 million average, a move of about 1.9 times its own 20-day ATR. None of the four pieces gives a reason for the drop. GuruFocus frames it on valuation: price $18.72 against a GF Value of $15.40, so 21.6% overvalued, GF Score 78/100 with growth at 8/10 but financial strength and valuation both 5/10, and net insider selling of $5.4 million over twelve months ($0.5 million bought, $5.9 million sold). The stock is down 10.4% year to date and 50.3% over a year. Cutting the other way, Citizens reiterated Market Outperform with a $25 target, set at roughly 10 times its 2027 GAAP EPS estimate, arguing the B2B2C model is hard to replicate given complex sales and integration cycles, with direct integrations into over 30 lenders' origination platforms and a training-data network effect a standalone underwriter can't copy. Second-look or turn-down underwriting is now about 50% of volume. The same piece notes Q2 2026 adjusted EPS of $1.07 on revenue of $365.63 million against consensus of $0.33 and $356.54 million, and record GAAP EPS of $0.49. Next earnings are estimated for 10 November.
Butterfly Network off 7.4%, Needham starts at Buy
BFLY was down 7.4%. There's a Form 144 filed for 23 September, but the item carries no detail beyond the title, so there's nothing to read into it on the numbers. Separately, Needham initiated coverage with a Buy on 22 September, following TD Cowen reiterating Buy on 11 September. The Fintel write-up puts the analyst consensus target mean and median at $10.71 as of 15 September, unchanged from 28 August, against a $8.14 close on 21 September, and counts 11 recommendations, 3 strong buy, 7 buy, 1 hold. Last quarter, reported 30 July, showed EPS of -$0.05 against a -$0.0587 estimate and revenue of $32.6 million versus $29.9 million expected.
Xenon down 6.5%, azetukalner depression trials paused
XENE is down 6.5% on the quote. The TradingView write-up covers a separate and much larger session, a 30.69% drop to $39.75 on 17.95 million shares against a 1.26 million 30-day average, market cap falling to about $3.85 billion. The cause given is that Xenon paused new enrolment in trials of azetukalner for depression after neuropsychiatric adverse events not seen in earlier testing. Trials already running continue with current participants, data expected in early 2027. That landed alongside the NDA submission to the FDA for azetukalner in focal seizures, which remains under review. The piece notes RSI(14) at 13.87 and every moving average from the 10-day to the 200-day above the price, and Q3 earnings expected around 11 November with an EPS estimate of -$1.13. There's also a TD Cowen neuropsychiatry conference transcript with CEO Ian Mortimer and CFO Tucker Kelly from 23 September, but the accessible portion is paywalled after the opening question, so there's no substance from it beyond the fact that management addressed "the update from last week."
AST SpaceMobile down 5.8%, heavy options volume
ASTS fell 5.8%, and neither full-text item explains it. One is a bullish chart post from a TradingView user citing a tightening consolidation and MACD momentum, which is one trader's opinion rather than news. The other, from 22 September, flags 118,093 ASTS option contracts traded, about 11.8 million underlying shares or 119.6% of the 9.9 million average daily volume, with 10,009 contracts on the $70 strike call expiring 25 September.
TeraWulf down 5.7% despite UBS Buy initiation
WULF fell 5.7% to $16.35, again with no stated cause in the material. The day's news was UBS initiating at Buy with a $24 target. UBS counts 840MW of IT leases signed to date, 60MW with Core42, 378MW with Fluidstack/Google and 402MW directly with Anthropic, representing average annual revenue of roughly $1.8 billion and NOI of about $1.5 billion, or $1.2 billion in the initial years at stabilisation, against trailing twelve-month revenue of $165 million. Only 102MW has been delivered so far, 23% of the Lake Mariner campus and about 12% of contracted capacity. UBS puts equity value creation at roughly $12 million per MW, implying up to about $30 a share from full lease-up, and points to a 2.1GW pipeline including roughly 800MW at a former eastern Kentucky strip mine with power from late 2028 and about 800MW at a former Maryland coal plant. That makes at least six initiations in a month: William Blair Outperform on 28 August, Freedom Capital Buy on 8 September, Wells Fargo Overweight on 17 September, Rothschild Neutral on 21 September, plus UBS, with the consensus target mean at $35.57 as of 15 September. GuruFocus takes the other side hard, GF Score 37/100 with growth 0/10 and profitability 1/10, GF Value of $5.70 against the price, forward P/E of 244x, and net insider selling of $35.6 million over twelve months. There's also a Form 144 filed for 22 September, no detail given. Q2, reported 5 August, was EPS of -$1.92 against -$0.23 expected on revenue of $44.8 million versus $47.3 million.
AngloGold down 5.6%, Moody's outlook raised
AU fell 5.6% to $98.74. Two headline-only items say Moody's raised its rating outlook on AngloGold Ashanti to positive; no further detail is given in them. The GuruFocus piece is purely a valuation read with no cause for the drop: GF Value $65.55 against the price, so 50.6% overvalued on that measure, GF Score 80/100 with growth 9/10 and profitability 8/10 but valuation and momentum both 3/10, trailing P/E of 13.2x versus a five-year median of 18.9x, and nine gurus holding, six adding and three trimming.
CRSP, VICR, NVTS, AXSM on headlines only
Four more names moved 5% or so. CRISPR Therapeutics fell 5.5%, with two GuruFocus headlines tying the dip to Anthropic's AI enzyme discovery and its new AI-driven biology research push. Vicor rose 5.5%, and the headlines point to Roth Capital maintaining a $375 target, a GF Score of 81/100, a raised Q3 outlook attributed to AI licensing momentum, and Vicor appearing among Tuesday's market cap movers alongside Amgen. Navitas fell 5.0%, with a GuruFocus valuation headline and an 8-K filed 23 September whose contents aren't described. Axsome fell 4.8%, on a fourth consecutive down day per one chart post, while Truist maintained Buy and raised its target to $285.
SpaceX cluster, down 4.1%
SPCX fell 4.1% and carries the densest headline flow of the day, all headline-only. Gwynne Shotwell is reported to be selling about $52 million of stock, there's another share unlock coming with investors watching supply, and Trump's financial disclosure showed he bought and sold SpaceX shares in July. On the business side, headlines cite a Grok bot user surge, Boeing and GoGo testing a satellite-linked military drone positioned against Starlink, and an IBD piece on Verizon being seen to lead the 2027 spectrum auction with SpaceX in the picture.
SanDisk, Nebius and the AI-hardware complex
SNDK fell 3.7% against a thick run of bullish headlines, breakout chart posts, a 7% surge noted in one piece and a $2,400 target referenced in two others, plus IBD coverage of Micron and Sandisk hitting buy signals. Nebius fell 4.0%, with several Michael Burry headlines warning on AI names and Micron specifically, and an ETF outflow note. Elsewhere in the same complex: Broadcom down 2.6% with an Investing.com piece asking why shares fell and an FT report that China is reviewing Broadcom switch use in state-backed data centres, Astera Labs down 0.8%, Amphenol down 0.8% with Bernstein initiating at Outperform and BNP raising its target to $110, TSMC down 1.2%, Vertiv down 1.8% on an agreement to acquire King Environmental Services for EMEA expansion, and Credo up 0.7% on an insider sale by its chief legal officer.
Oracle down 3.1%
ORCL fell 3.1% with a lot of headline traffic and no single driver. One X post says Oracle sent a force majeure notice over a New Mexico data centre. Oracle Japan's Q1 FY27 results showed cloud revenue up 32% with margin expansion. There are multiple insider sales, CEO Michael Sicilia $3.42 million and EVP Maria Smith $399,122, plus a Form 144 and Form 4. Other headlines cover an expanded digital assets platform for banking and two pieces on AI borrowers paying a 37 basis point debt premium.
Apple and the rest
AAPL was down 0.8% on a very long headline list: a long-term Qualcomm patent deal easing revenue fears, BofA reiterating a $370 target while flagging mixed iPhone 18 demand, UBS reiterating Neutral on iPhone wait times, the Trump administration backing Apple in the Epic Supreme Court case, new Mac mini and Mac Studio models aimed at local AI, and reports Apple is exploring a screenless fitness tracker. Netflix, down 1.1%, was downgraded by HSBC with the target cut to $76 on the YouTube viewership threat. Rocket Lab fell 2.3% while Cathie Wood's ARK bought roughly $25 million of shares and sold Alphabet. AMC fell 3.4% after pricing $2 billion of notes and an $850 million loan. On Holding rose 2.6% after an investor day setting a CHF 5.6 billion revenue goal for 2029 plus a buyback, with Needham raising its target to $40. Quieter names with single notes: Generac -3.3%, Planet -3.1% on an Amazon biodiversity monitoring launch, Incyte, SoundHound with Piper cutting to $6, NetApp +1.8% on CEO and director share sales, Mercury Systems, Teva with Oppenheimer initiating at Outperform, Revolution Medicines with Goldman reinitiating Buy at $267, Exelixis, Iovance with Goldman reinstating Buy at $15, Aflac, Take-Two ahead of GTA VI, and Costco, which reports fiscal Q4 after the close with consensus EPS of $6.48.
TradingView
Trading 212
